Latest Period
Q1 2026
Security Snapshot
Tyra Biosciences, Inc. - Common Stock, $0.0001 par value per share (TYRA) Institutional Ownership
CUSIP: 90240B106
13F Institutional Holders and Ownership History from Q3 2021 to Q1 2026
Institutions Reporting
163
Shares (Excl. Options)
65,938,350
Price
$38.30
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Type / Class
- Equity / Common Stock, $0.0001 par value per share
- Symbol
- TYRA on Nasdaq
- Shares outstanding
- 58,928,571
- Price per share
- $33.79
- All holders as of 31 Mar 2026
- Q1 2026
- Total 13F shares
- 65,938,350
- Total reported value
- $2,524,645,151
- % of total 13F portfolios
- 0.01%
- Share change
- +9,055,332
- Value change
- +$382,078,973
- Number of holders
- 163
- Price from insider filings
- $33.79
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Key facts
- TYRA - Tyra Biosciences, Inc. - Common Stock, $0.0001 par value per share is tracked under CUSIP 90240B106.
- 163 institutions reported positions in Q1 2026.
- 10 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 133 to 163 between Q4 2025 and Q1 2026.
- Reported value moved from $1,493,991,866 to $2,524,645,151.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC Evidence
Latest holder context comes from 163 institutions filings for Q1 2026.
Security key
90240B106
Latest holder period
Q1 2026
13F holders
163
13D/G owners
10
CIK / CUSIP context first
Open Q1 2026 holders
TYRA full holder history
Tyra Biosciences, Inc. SEC filings
Tyra Biosciences, Inc. company facts
Tyra Biosciences, Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 90240B106:
Significant Owners of Tyra Biosciences, Inc. - Common Stock, $0.0001 par value per share (TYRA) based on Schedule 13D/G filings
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | 21% | -5.5% | $380,263,825 | +$11,370,397 | 12,266,575 | +3.1% | RA Capital Management, L.P. | 04 Mar 2026 |
| FMR LLC | 14% | +373% | $296,738,016 | +$231,353,566 | 7,747,648 | +354% | FMR LLC | 31 Mar 2026 |
| JANUS HENDERSON GROUP PLC | 7.2% | +36% | $148,931,747 | +$39,592,966 | 3,890,589 | +36% | JANUS HENDERSON GROUP PLC | 31 Mar 2026 |
| Farallon Capital Partners, L.P. | 6.6% | +17% | $137,073,713 | +$22,814,880 | 3,580,818 | +20% | Dapice Joshua J. | 31 Mar 2026 |
| Harris Todd | 4.8% | -6% | $111,522,732 | +$3,788,304 | 2,913,342 | +3.5% | Todd Harris | 31 Mar 2026 |
| TCG Crossover GP I, LLC | 5.7% | $29,792,499 | 2,898,103 | TCG Crossover GP I, LLC | 27 Feb 2025 | |||
| Commodore Capital LP | 4.2% | -35% | $94,743,000 | -$34,452,000 | 2,475,000 | -27% | Commodore Capital LP | 31 Mar 2026 |
| Vestal Point Capital, LP | 4.5% | -18% | $33,925,750 | -$6,363,058 | 2,425,000 | -16% | Vestal Point Capital, LP | 30 Sep 2025 |
| BIOTECHNOLOGY VALUE FUND L P | 4% | -48% | $64,574,633 | -$55,131,655 | 2,127,665 | -46% | BVF PARTNERS L P/IL | 31 Dec 2025 |
| Canaan XI L.P. | 1.4% | -68% | $28,725,000 | -$83,511,005 | 750,000 | -74% | Canaan XI L.P. | 31 Mar 2026 |
As of 31 Mar 2026, 163 institutional investors reported holding 65,938,350 shares of Tyra Biosciences, Inc. - Common Stock, $0.0001 par value per share (TYRA). This represents 112% of the company’s total 58,928,571 outstanding shares.
Top 25 Institutional Shareholders
The largest institutional shareholders of Tyra Biosciences, Inc. - Common Stock, $0.0001 par value per share (TYRA) together control 100% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | 21% | 12,198,625 | 0% | 5% | $467,207,338 |
| FMR LLC | 13% | 7,747,648 | +61570% | 0.02% | $296,734,917 |
| Nextech Invest, Ltd. | 6.9% | 4,055,861 | 0% | 11% | $155,339,476 |
| JANUS HENDERSON GROUP PLC | 6.6% | 3,890,589 | +33% | 0.07% | $148,867,244 |
| Alta Partners Management Company, L.P. | 6.5% | 3,823,425 | 0% | 97% | $146,437,178 |
| FARALLON CAPITAL MANAGEMENT LLC | 6.1% | 3,580,818 | +73% | 0.89% | $137,145,329 |
| TCG Crossover Management, LLC | 5.5% | 3,248,980 | +12% | 3.6% | $124,435,934 |
| Commodore Capital LP | 4.2% | 2,475,000 | -27% | 5.5% | $94,792,500 |
| BlackRock, Inc. | 3.8% | 2,217,929 | +6.3% | 0% | $84,946,671 |
| Paradigm Biocapital Advisors LP | 3.5% | 2,054,991 | 1.6% | $78,706,155 | |
| BVF INC/IL | 3.4% | 1,976,196 | -7.1% | 2.4% | $75,688,307 |
| Caligan Partners LP | 2.2% | 1,276,968 | +35% | 3.5% | $48,907,874 |
| STATE STREET CORP | 2.1% | 1,216,078 | +62% | 0% | $46,575,787 |
| VANGUARD CAPITAL MANAGEMENT LLC | 1.9% | 1,125,970 | 0% | 0% | $43,124,651 |
| 5AM Venture Management, LLC | 1.7% | 1,029,298 | 0% | 11% | $39,422,113 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 1.7% | 986,061 | +6732% | 0% | $37,767,000 |
| Logos Global Management LP | 1.4% | 850,000 | +305% | 1.7% | $32,555,000 |
| BARCLAYS PLC | 1.4% | 833,399 | +992% | 0.01% | $31,919,181 |
| Canaan Partners XI LLC | 1.3% | 750,000 | -78% | 38% | $28,725,000 |
| GEODE CAPITAL MANAGEMENT, LLC | 1.1% | 658,482 | +0.11% | 0% | $25,225,567 |
| JENNISON ASSOCIATES LLC | 1.1% | 632,432 | 0.02% | $24,222,146 | |
| Sio Capital Management, LLC | 1% | 605,439 | +15% | 3.3% | $23,188,314 |
| GOLDMAN SACHS GROUP INC | 0.93% | 550,334 | +202% | 0% | $21,077,792 |
| DEERFIELD MANAGEMENT COMPANY, L.P. | 0.93% | 549,000 | 0.25% | $21,026,700 | |
| Balyasny Asset Management L.P. | 0.6% | 351,479 | -57% | 0.03% | $13,461,646 |
Institutional Holders of Tyra Biosciences, Inc. - Common Stock, $0.0001 par value per share (TYRA) across Reporting Periods
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 65,938,350 | $2,524,645,151 | +$382,078,973 | $38.30 | 163 |
| 2025 Q4 | 56,830,609 | $1,493,991,866 | +$12,760,989 | $26.29 | 133 |
| 2025 Q3 | 55,638,635 | $778,399,313 | -$9,877,671 | $13.99 | 115 |
| 2025 Q2 | 56,588,644 | $541,513,140 | +$28,813,504 | $9.57 | 120 |
| 2025 Q1 | 53,573,458 | $499,522,930 | +$34,676,031 | $9.30 | 116 |
| 2024 Q4 | 48,613,623 | $675,760,666 | -$145,254,713 | $13.90 | 112 |
| 2024 Q3 | 47,054,295 | $1,105,994,170 | +$8,152,750 | $23.51 | 94 |
| 2024 Q2 | 46,814,701 | $748,570,507 | -$1,810,347 | $15.99 | 76 |
| 2024 Q1 | 46,852,011 | $768,372,899 | +$182,484,246 | $16.40 | 75 |
| 2023 Q4 | 35,756,693 | $495,188,385 | -$9,797,725 | $13.85 | 62 |
| 2023 Q3 | 36,462,633 | $502,118,395 | +$3,284,853 | $13.77 | 59 |
| 2023 Q2 | 36,210,809 | $616,671,033 | +$8,028,494 | $17.03 | 59 |
| 2023 Q1 | 35,654,296 | $572,964,060 | +$8,455,742 | $16.07 | 50 |
| 2022 Q4 | 35,239,863 | $267,821,738 | -$5,207,345 | $7.60 | 45 |
| 2022 Q3 | 35,692,923 | $313,754,295 | -$403,922 | $8.79 | 43 |
| 2022 Q2 | 35,744,229 | $255,572,000 | -$3,322,156 | $7.15 | 44 |
| 2022 Q1 | 36,133,976 | $386,624,000 | -$8,627,515 | $10.70 | 46 |
| 2021 Q4 | 35,174,367 | $494,157,000 | +$13,654,547 | $14.07 | 45 |
| 2021 Q3 | 26,080,552 | $456,755,000 | +$456,755,000 | $17.59 | 25 |